Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NURSE.0000527596.79097.9a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cultural bias in the assessment of language: A closer look at the Boston naming test among multicultural Canadian older adults.
Appl Neuropsychol Adult
January 2025
Neuropsychology and Cognitive Health Program, Baycrest Health Sciences, Toronto, Canada.
Objective: The Boston Naming Test (BNT) is commonly used to assess word-finding in older adults but performance may be impacted by cultural and linguistic factors. This study aimed to assess cultural bias in BNT performance among older adults, explore sources of this bias and provide clinical guidelines for its use in multicultural settings.
Methods: We conducted a retrospective chart review of 525 older adults referred for neuropsychological assessment at a large geriatric hospital in a multicultural Canadian city.
Biomarkers.
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Munich, Bavaria, Germany.
Background: Alzheimer's disease (AD) is associated with substantial synaptic loss potentially due to synaptotoxicity of fibrillar tau, but the association between tau deposition and synaptic loss remains unclear. Based on previous observations that pathology spreads preferentially between closely connected regions, we tested in the current multi-PET tracer study the hypothesis that synaptic loss propagates to regions closely connected to epicenters of high tau accumulation.
Method: We assessed 18F-SynVesT-1 PET as a measure of synaptic vesicle glycoprotein 2A (SV2A), and 18F-flortaucipir tau-PET in fourty-five 18F-florbetapir-PET-positive (Aβ+) subjects with MCI or AD dementia, and 23 cognitivly normal (CN) Aβ- controls.
Background: Apolipoprotein ε4 allele (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). Compared with non-carriers, cognitively normal APOE4 individuals have shown brain atrophy and lower cerebral blood flow (CBF) decades before AD pathological and clinical symptoms appear. The goal of the study is to determine if using Sirolimus, an FDA-approved mTOR inhibitor, could restore the brain volumes in structures related to cognitive functions and global CBF (gCBF) for asymptomatic APOE4 carriers compared with non-carriers.
View Article and Find Full Text PDFAlzheimer's Imaging Consortium.
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Munich, Bavaria, Germany.
Background: Alzheimer's disease (AD) is associated with substantial synaptic loss potentially due to synaptotoxicity of fibrillar tau, but the association between tau deposition and synaptic loss remains unclear. Based on previous observations that pathology spreads preferentially between closely connected regions, we tested in the current multi-PET tracer study the hypothesis that synaptic loss propagates to regions closely connected to epicenters of high tau accumulation.
Method: We assessed 18F-SynVesT-1 PET as a measure of synaptic vesicle glycoprotein 2A (SV2A), and 18F-flortaucipir tau-PET in fourty-five 18F-florbetapir-PET-positive (Aß+) subjects with MCI or AD dementia, and 23 cognitivly normal (CN) Aß- controls.
Alzheimer's Imaging Consortium.
Alzheimers Dement
December 2024
University of Missouri - Columbia, Columbia, MO, USA.
Background: Apolipoprotein e4 allele (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). Compared with non-carriers, cognitively normal APOE4 individuals have shown brain atrophy and lower cerebral blood flow (CBF) decades before AD pathological and clinical symptoms appear. The goal of the study is to determine if using Sirolimus, an FDA-approved mTOR inhibitor, could restore the brain volumes in structures related to cognitive functions and global CBF (gCBF) for asymptomatic APOE4 carriers compared with non-carriers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!